Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 7 Brain Neoplasms 4 Pain 2 Neuralgia 2 Glioma 2 Depression 2 Visceral Pain 1 Recurrence 1 Rectal Neoplasms 1 Pituitary Neoplasms 1 Pancreatic Neoplasms 1 Neurologic Manifestations 1 Lymphoma, Follicular 1 Language Disorders 1 Headache 1 Glioblastoma 1 Fatigue 1 Depressive Disorder, Major 1 Cognitive Dysfunction 1 Carcinoma, Renal Cell 1 Cancer Survivor 1 Anxiety Disorders 1 Agnosia 1 Acromegaly 1

Interventions

Temozolomide 405 Radiotherapy 202 Bevacizumab 157 Radiation 80 Magnetic Resonance Spectroscopy 77 Lomustine 49 Surgical Procedures, Operative 45 Carmustine 41 pembrolizumab 40 Irinotecan 38 Nivolumab 32 Specimen Handling 28 Carboplatin 27 Radiosurgery 24 Erlotinib Hydrochloride 24 Drug Therapy 23 Chemotherapy, Adjuvant 23 Radiotherapy, Intensity-Modulated 22 Cyclophosphamide 20 Aminolevulinic Acid 20 O(6)-benzylguanine 17 sargramostim 16 Radiotherapy, Conformal 15 Blood Specimen Collection 15 temsirolimus 14 Granulocyte-Macrophage Colony-Stimulating Factor 14 Everolimus 14 Vorinostat 13 Sorafenib 13 Ipilimumab 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Glioblastoma × Transcranial Magnetic Stimulation × Clear all

NCT02283944 2021-09-20

TMS Electrochemotherapy for Glioblastoma Multiforme

University of Aarhus

Phase 2 Withdrawn

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡